lasmiditan

Lasmiditan is an oral small molecule medication used for the acute treatment of migraine attacks with or without aura in adults. It is not indicated for migraine prevention. Lasmiditan belongs to a novel class of antimigraine agents known as neurally-acting anti-migraine medications (NAAMAs) or "ditans." Its mechanism of action involves selective agonism at the serotonin 5-HT1F receptor, which is found on trigeminal ganglion neurons and within central pain pathways. Activation of this receptor inhibits the release of calcitonin gene-related peptide (CGRP) and glutamate, both key mediators in migraine pathophysiology. Unlike triptans, lasmiditan does not cause vasoconstriction and thus may be safer for patients with cardiovascular risk factors. The drug was developed by Eli Lilly and was first approved by the US FDA in 2020[3][4][5][6][7].

Brand names

Reyvow

Other names

lasmiditanLY573144LY-573144LY 573144Reyvow